For research use only. Not for therapeutic Use.
Avizakimab（Cat No.:I042168）is an investigational monoclonal antibody designed to target and inhibit IL-13 (interleukin-13), a cytokine involved in the immune response and inflammation. IL-13 is implicated in several chronic inflammatory and autoimmune conditions, including asthma, atopic dermatitis, and inflammatory bowel disease (IBD). By blocking IL-13, avizakimab aims to reduce inflammation, alleviate symptoms, and improve disease management. It is being studied in clinical trials to assess its safety and efficacy in treating allergic and inflammatory conditions, with the goal of offering patients improved control over chronic inflammatory diseases.
| Catalog Number | I042168 |
| CAS Number | 2229685-51-0 |
| Purity | ≥95% |
